Optison
FDA Approves First Drug-Eluting Stent to Treat Peripheral Arterial Disease »
"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
Read the FDA Approves First Drug-Eluting Stent to Treat Peripheral Arterial Disease article »
Optison
CONTRAINDICATIONS
Do not administer OPTISON to patients with known or suspected:
- Right-to-left, bi-directional, or transient right-to-left cardiac shunts,
- Hypersensitivity to perflutren, blood, blood products or albumin (see WARNINGS).
Do not administer OPTISON by intra-arterial injection.
Last reviewed on RxList: 9/6/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Optison Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Heart Health
Get the latest treatment options.
Updated & New
